ESTRO 2024 - Abstract Book

S1075

Clinical - Gynaecology

ESTRO 2024

89 patients with cervical cancer have been included in the study, and were followed for a median of 35.75 months. Mean age was 52.49, ranging between 22 and 80. 48.30% had stage III or more. 1 patient was metastatic on presentation. 85.4% of patients had squamous cell carcinoma, 13.5% had adenocarcinoma, and 1 patient had carcinoma with neuro-endocrine features. The majority of patients (58.4%) tested positive for P16. 100% of patients received radiotherapy at dose of 45Gy or more. 89.9% of patients received chemotherapy concurrently with radiotherapy. 2 patients received chemotherapy before and/or after definitive treatment. 33.7% of patients underwent surgical resection. Most patients (94.40%) received a radiation boost to the cervical primary tumor above 45Gy, either by brachytherapy (76.4%), EBRT sequentially or simultaneously with phase 1 of radiotherapy (18.0%), or both brachytherapy and EBRT boost (46%). A majority of patients, 80.9%, achieved either a complete radiologic or pathologic response, while the remaining 19.1% achieved a partial response. Among the 10 patients who experienced local recurrence, most of them (7) had symptoms that preceded the detection of recurrence. Local recurrence was identified in 2 patients through Pap smear examination, in 2 patients through physical examination, and in the most common manner, radiologically. Specifically, MRI detected local recurrence in 5 patients, and a PET/CT scan identified it in 1 patient. In total, 20 abnormal Pap smears were identified among 362 conducted during follow-up, affecting 14 patients. The most frequent observation was ASCUS, which was found in 12 patients. Among the abnormal Pap smears, 3 revealed invasive carcinoma, with 2 indicating squamous cell carcinoma and 1 indicating adenocarcinoma. Remarkably, 2 of these cases were linked to local recurrence.